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Abstract
Background—Infants born to women who receive intrapartum antibiotics may have higher rates
of infectious morbidity and mortality than unexposed infants.
Objective—To determine the association of maternal intrapartum antibiotics and early neonatal
morbidity and mortality.
Methods—Secondary analysis of data from a multi-site randomized placebo-controlled clinical
trial of antibiotics to prevent chorioamnionitis-associated mother-to-child transmission of HIV-1 and
preterm birth in sub-Saharan Africa. Early neonatal morbidity and mortality were analyzed. In an
intent-to-treat (ITT) analysis, infants born to women randomized to antibiotics or placebo were
compared. Additionally, non-ITT analysis was performed because some women received non-study
antibiotics for various clinical indications.
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Results—Overall, 2659 pregnant women were randomized. Of these, 2466 HIV-1-infected and -
uninfected women delivered 2413 live born and 84 stillborn infants. In the ITT analysis, there were
no significant associations between exposure to antibiotics and early neonatal outcomes. Non-ITT
analyses showed more illness at birth (11.2% vs. 8.6%, p=0.03) and more admissions to the Special
Care Baby Unit (12.6% vs. 9.8%, p = 0.04) among infants exposed to maternal intrapartum antibiotics
than among unexposed infants. Further analyses revealed greater early neonatal morbidity and
mortality among infants of mothers who received non-study antibiotics than of mothers who received
study antibiotics.
Conclusion—There is no association between intrapartum exposure to antibiotics and early
neonatal morbidity or mortality. The associations observed in non-ITT analyses are most likely the
result of women with peripartum illnesses being more likely to receive non-study antibiotics.
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INTRODUCTION
Perinatal mortality and morbidity are significant global health problems. The major causes of
perinatal deaths include preterm birth, neonatal infection and asphyxia1, 2. However, the roles
of other factors that may predispose neonates to these direct causes of mortality are less well
understood. Pregnant women may receive antibiotics during the antepartum period or during
labor for various reasons, including treatment of syphilis and bacterial vaginosis (BV) or the
prevention of preterm labor and adverse outcomes associated with pre-labor rupture of
membranes (PROM). Such treatment with antibiotics may benefit the neonate either by
eliminating maternal infection or by treating intrauterine fetal infection if the antibiotic crosses
the placenta. In such cases, there is a clear benefit to the baby. However, it is also known that
intrapartum antibiotic use may be associated with adverse effects in late neonatal life, including
increased frequency of neonatal infection and necrotizing enterocolitis3 or delayed clinical or
microbiological diagnosis of neonatal infections and development of antibiotic resistance4–6.
These reports do not differentiate early from late onset neonatal morbidity and mortality that
may result from intrapartum antibiotic exposure. There is also a possibility that transplacental
transfer of antibiotics used for maternal indications may result in sub-therapeutic levels in the
neonate and contribute to early neonatal morbidity. This may in turn increase the number of
neonates admitted to and who die in a special care baby unit, due to early neonatal disease.
We therefore analyzed data from a randomized clinical trial of antibiotics to reduce
chorioamnionitis-related mother-to-child transmission (MTCT) of HIV and preterm birth7. In
this trial, mothers received antibiotics (erythromycin and metronidazole) antepartum starting
at 20–24 weeks gestation and intrapartum (ampicillin and metronidazole) starting at onset of
labor. The antibiotics were chosen to ensure broad coverage against microorganisms associated
with BV, trichomoniasis and chorioamnionitis. The rates of BV and trichomoniasis8 were
reduced in the antibiotic group compared to the placebo group. However, the rates of
chorioamnionitis were not different following treatment with these antibiotics8. This may be
because the antibiotics were administered late after the subclinical (histological)
chorioamnionitis was already established. In a planned secondary analysis, we hypothesized
that infants born to women who received intrapartum antibiotics would have higher rates of
infectious morbidity and mortality than would infants born to women who did not receive
intrapartum antibiotics. The main objective of this analysis was to evaluate the association
between intrapartum exposure to antibiotics and early neonatal health.
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Study design, population and procedures
HPTN 024 was a randomized, double blind, placebo-controlled, phase III study of antibiotics
to reduce MTCT of HIV. This trial has been previously described in detail7–8. It was conducted
in four African sites: Blantyre and Lilongwe (Malawi), Lusaka (Zambia) and Dar es Salaam
(Tanzania). Enrollment began in July 2001, and the last delivery occurred in August 2003. This
study was approved by appropriate Institutional Review Boards in Zambia, Malawi, and
Tanzania and in the U.S. at Johns Hopkins University, University of Alabama at Birmingham,
University of North Carolina at Chapel Hill, and Harvard University. All women were
counseled and provided written informed consent.
Enrollment of HIV-1-infected women at 20–24 weeks’ gestation was based on serologically
confirmed HIV-1 infection status. In addition to HIV-1-infected women, HIV-1-uninfected
women were enrolled at three of the four study sites (one HIV-1-uninfected woman for every
five HIV-1-infected women enrolled). HIV-1-uninfected women were included in the trial to
reduce stigma among HIV-1-infected women enrolled in the study, and to ensure
generalizability of results of the study, especially with regard to the effect of antibiotic
treatment on preterm birth8.
At 20–24 weeks of pregnancy, all enrolled women received either antibiotics (metronidazole
250 mg and erythromycin 250 mg) or identically appearing placebos, all drugs administered
orally three times a day for seven days. With the onset of labor contractions and/or pre-labor
rupture of membranes (PROM), study participants initiated a second oral course of antibiotics
consisting of metronidazole 250 mg and ampicillin 500 mg, or identically appearing placebos,
every four hours until delivery and continued postpartum for a total of seven days. When data
presented at an interim Data Safety and Monitoring Board review justified the conclusion that
the antibiotic regimen did not reduce MTCT of HIV-1, the protocol team was advised to cease
enrollment; thus no further participants were recruited as of February 21, 2003. No further
antibiotics were administered after this decision was made and therefore some enrolled women
did not receive study intrapartum antibiotics.
HIV-1-infected women were provided with nevirapine (NVP) prophylaxis according to the
HIVNET 012 regimen9. Women also received antibiotic treatment for any clinical indication
for which an antibiotic was indicated. Structured questionnaires were used to collect
information on maternal demographics, obstetric history, medical history, sexual history, as
well as use of concomitant antibiotics and other medications.
Study population and definitions for this analysis
The inclusion criterion for this analysis was: live born infants born to women (both HIV-1-
infected and uninfected) enrolled in the HPTN 024 trial. The initial analysis was based on
intention-to-treat (ITT). However, some women who were randomized to the treatment arm
did not receive study antibiotics (mainly because they did not deliver at the study clinic) while
other women randomized to placebo arm received (non-study) antibiotics. Therefore, further
analysis based on “actual” maternal receipt or non-receipt of intrapartum antibiotics also was
performed (non-ITT analysis). To determine the actual receipt of antibiotics by women enrolled
in HPTN 024, we reviewed both generic and brand names of antimicrobial agents recorded on
the study concomitant medication form. Early neonatal morbidity included outcomes occurring
within the first seven days of life, based on the following variables: infant illness at birth,
admission to SCBU and duration of stay, and neonatal infections. Early neonatal mortality
meant deaths within the first seven days of life. Since admission to SCBU information was
extracted from the infant birth form, the analysis of this variable was restricted to infants born
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in the study hospital (88.1% antibiotic arm and 86.6% in the placebo arm, p= 0.25). Similarly,
discharge status refers to those admitted to the SCBU. The main trial was not designed to detect
associations between intrapartum antibiotics and neonatal morbidity and mortality. For this
secondary analysis, no separate power calculations were conducted.
Statistical analysis
Statistical analyses were conducted using SAS version 8.2. Independent two sample T-tests,
Fischer’s exact test and two sample chi-square tests were performed to compare means and
medians, respectively. Proportions of neonatal characteristics and outcomes were compared
using chi-square tests. Univariate logistic regression models were used to compute odds ratios
(ORs) and 95% confidence intervals (CIs) to evaluate the associations of intrapartum
antibiotics and neonatal outcomes.
RESULTS
Size and Characteristics of the Study Population
Overall, 2659 pregnant women were randomized antenatally. Of these, 193 were excluded,
and the remaining 2466 women delivered 2497 infants. Eighty-four infants (40 in the placebo
arm and 44 in the antibiotics arm) were excluded because they were stillborn. This analysis is
restricted to 2413 live born infants. Of these 1214 (166 from HIV-1-uninfected and 1048 from
HIV-1-infected mothers) were born to 1197 mothers randomized to antibiotics and 1199 (169
from HIV-1-uninfected, 1030 from HIV-1-infected mothers) were born to 1187 mothers in the
placebo arm (Figure 1). There were no significant differences in the maternal and infant
characteristics according to randomization arm (Table 1).
Analyses of Intrapartum Antibiotics and Early Neonatal Outcomes
In the ITT analysis, there were no differences between maternal intrapartum antibiotic receipt
and early neonatal morbidity and mortality (Table 2). The non-ITT cohort was defined as
infants born to women who either received or did not receive antepartum and intrapartum
antibiotics (including non-study antibiotics). The antibiotics used were penicillins (ampicillin,
crystalline penicillin, benzathine penicillin, amoxicillin, cloxacillin), metronidazole,
chloramphenicol, cotrimoxazole, erythromycin and gentamicin. The antibiotics were used for
cesarean section prophylaxis, PROM and chorioamnionitis, respiratory tract infections
(pneumonia, bronchitis, and upper respiratory tract infection), malaria, sepsis (breast abscess,
Bartholin’s abscess and paronychia), lower genital tract infection (BV and trichomoniasis),
genital ulcer disease including syphilis, gastroenteritis including dysentery and urinary tract
infection. In the non-ITT analysis (based on the actual receipt of antibiotics Table 3), there
were more infant illnesses at birth among those born to mothers who received intrapartum
antibiotics than among those born to women who did not receive antibiotics (p = 0.03). Most
of the infant illnesses occurring at birth were infections, including congenital pneumonia,
neonatal sepsis, pyrexia of unknown etiology and umbilical cord infection. The non-infectious
illnesses were asphyxia, respiratory distress syndrome, neonatal jaundice,
hepatosplenomegaly, hypoglycemia, hypothermia, hypoxic encephalopathy, transient apnea
of the newborn, dysmaturity, umbilical cord hemorrhage and, more rarely, congenital
anomalies such as anal atresia. In addition, the number of infants admitted to SCBU was
significantly higher in neonates exposed to intrapartum antibiotics than neonates who were not
exposed to antibiotics (p = 0.04). However, differences in early neonatal infection, duration of
stay in SCBU, early neonatal deaths and deaths due to infectious causes were not statistically
significant in the two groups.
There were no statistically significant differences between infants exposed and not exposed to
intrapartum antibiotics and neonatal infections occurring within the first week of birth, duration
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of stay in the special care baby unit, death before discharge or status at discharge from hospital.
There were also no statistically significant differences in the reported causes of death for the
infants who died in the SCBU (data not shown). The cause of death was in most cases based
on clinical judgment by the investigators at the study sites. The commonest cause was infections
[15.5% (13/84)] followed by congenital anomalies [7.1% (6/84)]. Although the proportion of
deaths due to an infectious etiology among the exposed infants was higher in the exposed group
(8/37 or 21.6%) than the unexposed (5/47 or 10.6%), this difference was not statistically
significant (p= 0.23), Table 3.
With respect to HIV-1 infection status of the mother and infant HIV-1 exposure at birth, the
maternal and infant characteristics and rates of neonatal infections and neonatal deaths were
similar in neonates exposed to intrapartum antibiotics compared to the antibiotic unexposed
group (data not shown). This was true for both analyses based on ITT and non-ITT. However,
the frequency of neonatal infections among neonates with unknown HIV-1 infection status at
birth (5.6% vs. 0%, p=0.02) was higher among those whose mothers received intrapartum
antibiotics (Table 3).
Additional non-ITT analyses were performed to further evaluate early neonatal outcomes
according to not only maternal receipt or non-receipt of intrapartum antibiotics, but also
according to whether, if intrapartum antibiotics were received, these were study antibiotics or
non-study antibiotics (Table 4). There were three categories of intrapartum antibiotic receipts:
“yes” - received study antibiotics, “yes” - received non-study antibiotics, and “no” - did not
receive antibiotics at all. The proportion of mothers who delivered at a study hospital differed
significantly according to maternal intrapartum antibiotic receipt category. Similarly, all infant
characteristics at birth (except gender) varied significantly according to maternal intrapartum
antibiotic receipt: birth weight, Ballard score, Apgar score, and infant illness at birth. Two
infant outcomes varied by maternal intrapartum antibiotic receipt category: admission to the
SCBU and early neonatal mortality.
Additionally, mothers who received non-study antibiotics were more likely to have rupture of
membranes > 4 hours (31.6%) than mothers who received study antibiotics (20.2%) or no
antibiotics (17.2%) (p<0.0001). Women who received non-study antibiotics also were more
likely to have clinical and histological chorioamnionitis (1.3% and 40.4%, respectively) than
women who received study antibiotics (0.3% and 35.9%, respectively) or no antibiotics (0.2%
and 34.5%, respectively). The differences in clinical chorioamnionitis among the three groups
of women were statistically significant (p=0.04) but not significant (p=0.37) for histological
chorioamnionitis. The proportion of infants who died of infectious causes and born to mothers
who received or did not receive antibiotics were not significantly different (26.1% [95% CI
8.1 – 44.0], 14.3% [95% CI 0 – 32.6] and 10.6% [95% CI 1.8 – 19.4] if the mother received,
respectively, study antibiotic, non-study antibiotic and no antibiotic, p=0.27), Table 4.
DISCUSSION
In the ITT analysis, there were no effects observed between maternal intrapartum receipt of
antibiotics and early neonatal morbidity or mortality. In non-ITT analyses, a greater proportion
of infants born to women who received intrapartum antibiotics had illnesses at birth and
admission to the SCBU. However, upon further analysis i.e. intrapartum antibiotic receipt
categorization analysis (Table 4), the greatest early neonatal morbidity and mortality were
observed among those infants whose mothers received non-study antibiotics, compared to
infants of mothers who received study antibiotics or who did not receive antibiotics at all. These
results suggest sicker women, who received antibiotics for a reason other than participation in
and randomization to antibiotics, had infants with greater early neonatal morbidity and
mortality because of the underlying maternal illness – and not because of exposure to the
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antibiotics per se. This interpretation is supported by the observation that more mothers with
prolonged rupture of membranes (and subsequently chorioamnionitis) were among those who
received antibiotics. It is a common practice in obstetrics to treat women with PROM and
chorioamnionitis with antibiotics.
Other studies have shown increased risks of neonatal sepsis due to drug-resistant
microorganisms among infants of mothers treated with intrapartum antibiotics compared to
unexposed infants6,10,11. The underlying mechanism may be a sub-therapeutic antibiotic level
in such infants. Contrary to these findings, we did not find increased rates of neonatal infection
associated with maternal intrapartum antibiotic receipt, perhaps because we confined our
analysis to the early neonatal period. Additionally, diagnostic capabilities were limited at the
study sites where most of the neonatal outcomes were based on clinical criteria and laboratory
confirmation was not consistently available. Bacterial resistance testing was not performed.
Therefore, under-estimation of early neonatal morbidity may have occurred.
Infants may become exposed to maternal antibiotics either through the placental route or
through breast milk. In the areas where this study was performed, breastfeeding is nearly
universal12 and is usually initiated soon after birth. Previously published data have suggested
an increased risk for late onset neonatal sepsis in infants exposed to peripartum antibiotics4.
Our analysis showed no association between exposure to intrapartum antibiotics and early
neonatal infection. This finding is similar to previous reports that did not find evidence of
potential adverse effects of intrapartum antibiotics and late onset neonatal disease. However,
our data suggest there may not be a difference in the adverse outcomes of antibiotics between
late onset and early onset infectious morbidity and mortality. This finding means that clinicians
may be more comfortable addressing early neonatal life safety concerns when prescribing
antibiotics for pregnant women intrapartum. They should be more able than before to give
appropriate advice when asked questions such as, “Will my baby be alright doctor if I take
these antibiotics during labor?”.
Further evaluation of the role of intrapartum antibiotics on early neonatal morbidity and
mortality as the primary outcome in resource-constrained settings is needed. The design of
such studies should take into account confounding factors such as PROM and other maternal
infectious conditions that are firstly, indications of antibiotics in the intrapartum period and,
secondly, determinants of early neonatal infectious morbidity and mortality. The influence of
both maternal and infant HIV infection in these populations should be part of the focus for
future studies. Such data may be invaluable in both clarifying the contradictory findings in the
literature and in guiding more rational antibiotic use in pregnancy and labor in resource-limited
countries.
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Randomization profile of mothers and infants in HPTN 024 Study.
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